Climb Bio, Inc. (CLYM)

Climb Bio, Inc. is trading at $17.23, down 1.20% on the session. The 50 day average sits at $12.66 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 74.4, which reads as overbought, and MACD is bullish crossover. Volume is volume spike.

The nearest support is around $12.34 with resistance near $17.00, so that band frames the current range. Average daily movement is roughly $1.07, or about 6.2% of the share price, which is what any stop placement has to allow for. The overall health score of 67 out of 100 combines a trend score of 75, momentum of 84 and a risk score of 30.

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.